TOKYO, September 18, 2019 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that it has been selected for the fifth time and 2nd consecutive year as an index component of the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific). This index is the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which is one of the world’s premier indices for Socially Responsible Investment (SRI).

The DJSI is a leading SRI index, developed jointly by S&P Dow Jones Indices LLC of the United States and RobecoSAM AG of Switzerland, which serves as one of the most important indices for investors who take into consideration the corporate social responsibility (CSR) initiatives of each company. Leading sustainability-driven companies are selected as the index component every year based on the assessment in terms of long-term economic, environmental, and social criteria.

In the mid-term business plan IBI 21 which runs for three years starting from 2019, Chugai has set five strategies to achieve the goal to accelerate corporate and social development through innovation focused on innovative medicines. In the fifth strategy “Strengthen Sustainable Platforms,” we have specified six priority areas that support our challenge toward innovation, in order to realize creation of shared values with the society. As a result, Chugai received substantially high scores compared to last year in categories related to “Healthcare access” and “Supply chain management.”

Based on the business philosophy of “Innovation all for the patients,” Chugai is committed to actively fulfill our social responsibilities as a healthcare company, by adding exceptional value through the creation of innovative medical products and services for the benefit of the medical community and human health around the world.